Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)
Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –
Halozyme Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Halozyme Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $611.93M, down 11.7% year over year. For fiscal 2025 it was $480.40M, down 14.5% from the year before. The highest annual figure on record is $561.74M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.40M | -14.5% |
| FY2024 | Dec 31, 2024 | $561.74M | +61.1% |
| FY2023 | Dec 31, 2023 | $348.66M | +27.2% |
| FY2022 | Dec 31, 2022 | $274.02M | -1.7% |
| FY2021 | Dec 31, 2021 | $278.90M | +89.0% |
| FY2020 | Dec 31, 2020 | $147.54M | – |
| FY2019 | Dec 31, 2019 | -$63.54M | – |
| FY2018 | Dec 31, 2018 | -$66.94M | -180.5% |
| FY2017 | Dec 31, 2017 | $83.16M | – |
| FY2016 | Dec 31, 2016 | -$80.80M | – |
| FY2015 | Dec 31, 2015 | -$25.78M | – |
| FY2014 | Dec 31, 2014 | -$61.27M | – |
| FY2013 | Dec 31, 2013 | -$79.21M | – |
| FY2012 | Dec 31, 2012 | -$52.55M | – |
| FY2011 | Dec 31, 2011 | -$18.74M | – |
| FY2010 | Dec 31, 2010 | -$52.75M | – |
| FY2009 | Dec 31, 2009 | -$57.01M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $292.15M | +42.4% |
| Q1 FY2026 | Mar 31, 2026 | $188.74M | +30.9% |
| Q4 FY2025 | Dec 31, 2025 | -$89.59M | -150.3% |
| Q3 FY2025 | Sep 30, 2025 | $220.62M | +33.1% |
| Q2 FY2025 | Jun 30, 2025 | $205.14M | +71.2% |
| Q1 FY2025 | Mar 31, 2025 | $144.22M | +47.2% |
| Q4 FY2024 | Dec 31, 2024 | $178.15M | +71.4% |
| Q3 FY2024 | Sep 30, 2024 | $165.80M | +82.2% |
| Q2 FY2024 | Jun 30, 2024 | $119.84M | +23.2% |
| Q1 FY2024 | Mar 31, 2024 | $97.99M | +73.7% |
| Q4 FY2023 | Dec 31, 2023 | $103.97M | +34.9% |
| Q3 FY2023 | Sep 30, 2023 | $90.98M | +6.7% |
| Q2 FY2023 | Jun 30, 2023 | $97.26M | +176.6% |
| Q1 FY2023 | Mar 31, 2023 | $56.42M | -26.2% |
| Q4 FY2022 | Dec 31, 2022 | $77.07M | +34.5% |
| Q3 FY2022 | Sep 30, 2022 | $85.29M | +11.8% |
| Q2 FY2022 | Jun 30, 2022 | $35.16M | -62.5% |
| Q1 FY2022 | Mar 31, 2022 | $76.45M | +48.5% |
| Q4 FY2021 | Dec 31, 2021 | $57.31M | -26.9% |
| Q3 FY2021 | Sep 30, 2021 | $76.29M | +85.6% |
| Q2 FY2021 | Jun 30, 2021 | $93.85M | +209.2% |
| Q1 FY2021 | Mar 31, 2021 | $51.47M | – |
| Q4 FY2020 | Dec 31, 2020 | $78.42M | – |
| Q3 FY2020 | Sep 30, 2020 | $41.10M | – |
| Q2 FY2020 | Jun 30, 2020 | $30.36M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.37M | -159.8% |
| Q4 FY2019 | Dec 31, 2019 | -$31.02M | -6076.9% |
| Q3 FY2019 | Sep 30, 2019 | -$23.54M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.98M | – |
| Q1 FY2019 | Mar 31, 2019 | $3.96M | – |
| Q4 FY2018 | Dec 31, 2018 | $519.00K | -99.6% |
| Q3 FY2018 | Sep 30, 2018 | -$24.87M | -390.0% |
| Q2 FY2018 | Jun 30, 2018 | -$19.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$23.15M | – |
| Q4 FY2017 | Dec 31, 2017 | $126.42M | – |
| Q3 FY2017 | Sep 30, 2017 | $8.58M | – |
| Q2 FY2017 | Jun 30, 2017 | -$24.88M | – |
| Q1 FY2017 | Mar 31, 2017 | -$26.92M | – |
| Q4 FY2016 | Dec 31, 2016 | -$21.93M | – |
| Q3 FY2016 | Sep 30, 2016 | -$22.04M | – |
See a number that looks wrong?